Discipline of Acute Care Medicine, University of Adelaide, Australia; Department of Intensive Care, Royal Adelaide Hospital, Australia.
Department of Intensive Care, Royal Melbourne Hospital, Australia.
Aust Crit Care. 2019 Sep;32(5):361-365. doi: 10.1016/j.aucc.2018.09.001. Epub 2018 Oct 19.
Approximately 9000 patients with type-2 diabetes mellitus (T2DM) are admitted to an intensive care unit (ICU) in Australia and New Zealand annually. For these patients, recent exploratory data suggest that targeting a more liberal blood glucose range during ICU admission may be safe and potentially beneficial. However, the current approach to blood glucose management of patients with T2DM in Australia and New Zealand ICUs is not well described, and there is uncertainty about clinician equipoise for trials of liberal glycaemic control in these patients.
The aim is to describe self-reported blood glucose management in patients with T2DM by intensivists working in Australian and New Zealand ICUs and to establish whether equipoise exists for a trial of liberal versus standard glycaemic control in such patients.
An online questionnaire of Australia and New Zealand intensivists conducted in July-September 2016.
Seventy-one intensivists responded. Forty-five (63%) used a basic nomogram to titrate insulin. Sixty-six (93%) reported that insulin was commenced at blood glucose concentrations >10 mmol/L and titrated to achieve a blood glucose concentration between 6.0 and 10.0 mmol/L. A majority of respondents (75%) indicated that there was insufficient evidence to define optimal blood glucose targets in patients with T2DM, and 59 (83%) were prepared to enrol such patients in a clinical trial to evaluate a more liberal approach.
A majority of respondents were uncertain about the optimal blood glucose target range for patients with T2DM and would enrol such patients in a comparative trial of conventional versus liberal blood glucose control.
每年约有 9000 名 2 型糖尿病(T2DM)患者入住澳大利亚和新西兰的重症监护病房(ICU)。对于这些患者,最近的探索性数据表明,在 ICU 入院期间将血糖目标设定得更宽松可能是安全且可能有益的。然而,目前澳大利亚和新西兰 ICU 中 T2DM 患者的血糖管理方法并未得到很好的描述,并且对于在这些患者中进行宽松血糖控制试验的临床医生是否存在平衡也存在不确定性。
旨在描述在澳大利亚和新西兰 ICU 工作的重症监护医师对 T2DM 患者的自我报告血糖管理情况,并确定在这些患者中进行宽松与标准血糖控制试验是否存在平衡。
2016 年 7 月至 9 月期间,对澳大利亚和新西兰的重症监护医师进行了在线问卷调查。
71 名重症监护医师作出了回应。45 名(63%)医师使用基本的诺模图来调整胰岛素剂量。66 名(93%)报告说,当血糖浓度>10mmol/L 时开始使用胰岛素,并将其滴定至血糖浓度在 6.0 至 10.0mmol/L 之间。大多数受访者(75%)表示,目前缺乏足够的证据来确定 T2DM 患者的最佳血糖目标,并且 59 名(83%)愿意招募这些患者参加临床试验,以评估更宽松的方法。
大多数受访者对 T2DM 患者的最佳血糖目标范围不确定,并且愿意将这些患者纳入常规与宽松血糖控制的比较试验中。